

INDEX

A

- Aboriginal *also see* Indigenous Australians
- high risk group..... 18–19, 40
 - liver cancer..... 15–16
 - prevalence..... 14–16, 35, 47
 - vaccination..... 15, 47, 50
- Acquired Immune Deficiency Syndrome (AIDS)..... 26, 78
- Actitest®..... 34
- acute infection..... 41, 43, 51, 53–4
- adefovir dipivoxil (ADV)..... 10, 25, 27–8, 55, 57, 59–62, 78, 103
- advanced liver disease..... 11–12, 18, 41–3, 65–8, 75, 78–9
- alanine aminotransferase (ALT).....
- 27, 31, 33–6, 41–3, 52–3, 57–60, 65, 77–8, 80, 97, 99, 103
- alpha fetoprotein estimation..... 53–5, 69–71, 77
- American Association of the Study of Liver Diseases (AASLD)..... 35, 41
- andrographis paniculata (green chiretta; Chuan Xin Lian)..... 98
- andrographolide..... 98
- anti-HBc..... 15, 17, 32, 34, 36, 52, 54, 80
- anti-HBc IgG..... 32, 43
- anti-HBc IgM..... 32, 34, 43, 52–3
- anti-HBe..... 32, 34, 36, 42–3, 52, 54, 58
- anti-HBs.....
- 26, 28, 32, 34, 36, 41, 46, 48–9, 52–4, 77–8, 80, 86–7, 103
- antiviral agents.....
- 10, 24, 26–7, 44, 55, 57–62, 65–6, 75–80, 97–8, 103
- *see also* adefovir dipivoxil (ADV); clevudine; complementary and alternative medicine (CAM); emtricitabine (FTC); entecavir (ETV); lamivudine (LMV); telbivudine (L-dT); tenofovir disoproxil fumarate (TDF) antiviral resistance *see* drug resistance
- apigenin (*Ocimum basilicum*)..... 96
- Artemisia annua* (Chinese wormwood; Qing Hao)..... 98
- artemunate..... 98
- ascites..... 11, 33, 52, 54, 67–8
- Asian-American Hepatitis B Program [New York]..... 72
- aspartate aminotransferase (AST)..... 35, 53, 99
- Astragalus membranaceus* (milk-vetch root; Huang Qi)..... 97–8
- Atractylis gummifera* (pine thistle)..... 96, 98
- Australian Acupuncture and Chinese Medicine Association (AACMA)..... 96, 99
- Australian Immunisation Handbook..... 50, 85–6
- Australian Medical Association (AMA)..... 90

B

- bilirubin..... 34, 54, 99
- black cohosh (*Actea racemosa* and *Cimicifuga racemosa*)..... 99
- blood product recipients..... 40, 46, 85
- body piercing..... 47, 85, 102
- Bupleurum chinensis* (Chai Hu)..... 97

C

- Cancer Council NSW..... 6–7
- Cancer Incidence in New South Wales Migrants 1991–2001 (Cancer Council NSW)..... 6
- Carlina gummifera*..... 96
- cART *see* Combination Antiretroviral Therapy
- CD4 T-cells..... 24
- CD8 T-cells..... 24
- Centers for Disease Control and Prevention [USA]..... 83
- chemotherapy..... 26, 69, 71, 80
- Chinese..... 15, 18, 70
- Chinese medicine..... 96–9
- chronic HBV
- age factors..... 41, 46, 51
 - clinical assessment..... 51–6
 - definition..... 9, 102
 - drug resistance..... 26–9
 - immune active phase..... 9–10
 - immune clearance phase..... 34, 41–3
 - immune control phase..... 34, 41–3, 53
 - immune escape phase..... 34, 41–3
 - immune tolerant phase..... 10, 34, 41–3, 59
 - liver damage..... 24, 42, 54–5, 58, 103
 - management in complex situations..... 75–80
 - mortality..... 44
 - natural history..... 40–4
 - paediatric management..... 77–8
 - referral guidelines..... 54
 - treatment..... 57–63
- chronic liver disease..... 15, 47, 49, 52, 66, 72, 85, 96
- cirrhosis
- compensated..... 11, 14
 - complementary medicine..... 96, 98–9
 - decompensated..... 10–11, 44, 60, 65–6, 71
 - definition..... 65

- HBV DNA level..... 31–2
 - HBV/HCV co-infection..... 79
 - HBV/HIV co-infection..... 78
 - HCC screening..... 56, 72
 - hepatocellular carcinoma (HCC)..... 70
 - liver biopsy results..... 33
 - monitoring..... 62, 67
 - mortality..... 44
 - prediction of development..... 33, 43, 53
 - pregnancy..... 76
 - risk factors..... 44, 51
 - cluvudine..... 27
 - clinical assessment..... 51–6
 - *see also* test results; testing
 - clotting disorder patients..... 46–7
 - coinfection
 - HBV- hepatitis D..... 44, 66, 78–9
 - HBV-HCV..... 17, 44, 78–9
 - HBV-HIV..... 27–8, 44, 63, 78–9
 - combination Antiretroviral Therapy (cART)..... 26, 78–80
 - combination therapy..... 29, 61–2, 78–9
 - complementary and alternative medicine (CAM)..... 11, 96–9
 - compound 861 (Cpd 861)..... 97–9
 - computed tomography (CT) scanning..... 66, 70
 - Comvax..... 48
 - confidentiality..... 90–5
 - contact tracing..... 37, 94–5
 - covalently closed circular (ccc) DNA..... 24–5, 43
 - criminal law..... 95
 - Culturally and Linguistically Diverse (CALD) communities
 - prevalence..... 14–15
 - vaccination..... 47, 50
- D**
- depression..... 59, 63
 - discrimination..... 19, 84, 91, 95
 - drug resistance..... 10, 24–9, 33, 55, 57–62, 77–8, 80
 - duty of care to third parties..... 95
- E**
- emtricitabine (FTC)..... 10, 27, 61, 78
 - Engerix-B..... 48–9
 - entecavir (ETV)..... 10, 25, 27–9, 55, 57, 59–62, 65, 78, 80, 103
 - epidemiology..... 13–19
 - ethics..... 90
 - exposure-prone procedures..... 52, 82, 86–7
- F**
- Fibroscan®..... 35
 - fibrosis *see* hepatic fibrosis
 - Fibrotest®..... 34–5
 - flares..... 42–3, 52, 55, 57–8, 60, 76, 79–80
 - flavonoids..... 96–8
 - fluid and electrolyte balance problems..... 66–7
 - fulminant hepatitis..... 43, 46, 54, 76–7, 79
- G**
- genotypes..... 33, 44, 59–60
 - genotyping..... 33
 - glomerulonephritis..... 52
 - gloves..... 84
 - glycyrrhiza root (licorice; Gan Cao) root..... 97
- H**
- H-B-VAX II..... 48
 - haemodialysis patients..... 35, 40, 47, 49, 85
 - hand hygiene..... 84
 - HBcAg..... 25–6, 52
 - HBeAg..... 10–11, 26, 31–4, 36, 41–3, 51–5, 57–60, 62, 76–80, 83, 97–8, 103
 - HBeAg-negative patients..... 10, 43, 52–3, 58–60, 76
 - HBeAg-positive patients..... 10, 32, 43, 51, 53, 55, 57–60, 62, 76
 - HBeAg seroconversion..... 10, 26, 32–3, 42, 55, 58–60, 98
 - HBIG..... 26, 46–7, 49–50, 76–7, 86–7
 - HBsAg..... 14–18, 24–6, 28, 31–2, 34, 36, 41–3, 46–9, 52–4, 58, 60, 76–80, 87, 97, 103
 - HBsAg-negative patients..... 43, 76, 78–80
 - HBsAg-positive patients..... 9, 11, 15–18, 35–6, 40–1, 43, 46–7, 49, 52, 54–5, 57, 78, 80
 - HBsAg seroconversion..... 10, 58, 60
 - HBV antigens..... 24, 26, 31
 - HBV DNA..... 24–6
 - genome..... 25, 32–3
 - level..... 10, 27, 31–4, 37, 42–4, 52–5, 57–9, 62, 65, 76, 78, 80, 83, 96–7, 99, 103
 - HBV DNA testing *see* testing
 - HBV-HCV coinfection..... 17, 44, 78–9
 - HBV-hepatitis D coinfection..... 44, 66, 78–9
 - HBV-HIV coinfection..... 27–8, 44, 63, 78–9
 - HBV Pol..... 25, 27–8
 - HBV-related liver disease projections..... 18
 - HCC *see* hepatocellular carcinoma health care workers
 - HBV infected..... 87
 - occupational exposure..... 47, 52, 82–8
 - vaccination..... 49, 82, 85, 87, 89, 104

<i>Health Records and Information Privacy Act 2002 (NSW)</i>	92
'healthy carrier'.....	41
Hepadnaviridae.....	24
hepatic decompensation.....	10, 51, 62, 65–6
hepatic encephalopathy.....	11, 52, 54
hepatic fibrosis.....	
.....	9–11, 31, 33–5, 37–8, 42, 44, 53, 59–60, 62, 65, 96–8
hepatic synthetic function.....	53
hepatitis A.....	37, 48, 52, 77
Hepatitis Australia.....	105
Hepatitis B immunoglobulin (HBIG) <i>see</i> HBIG.....	
hepatitis C.....	17–18,
35, 47, 51, 53–4, 63, 65–6, 68, 78–9, 82–3, 85–7, 104–5	
• <i>see also</i> HBV-HCV coinfection.....	
hepatitis D.....	43–4, 52, 54, 66, 78–9
hepatocellular carcinoma (HCC).....	69–72
• chronic hepatitis B.....	51
• cirrhosis.....	44, 70
• epidemiology.....	11
• ethnicity.....	15, 18, 69
• HBV DNA level.....	31, 44, 53
• high-risk communities.....	69–70
• incidence.....	14, 69–70
• Indigenous Australians.....	16
• lamivudine.....	60
• mortality.....	14, 69
• prediction of development.....	32–3, 43–4, 53, 65, 69
• prevention.....	71–2
• risk factors.....	44
• screening.....	55, 68, 70, 72
• treatment options.....	11, 71
• vaccination.....	46
hepatocytes.....	24–5, 43, 54, 80, 98
hepatoma <i>see</i> liver cancer.....	
high-risk behaviours.....	17–19, 40, 47
• <i>see also</i> exposure-prone procedures.....	
high-risk communities.....	6, 9, 14–18, 35, 40, 47, 72
highly active antiretroviral therapy (HAART) <i>see</i> cART.....	
Histological Activity Index (HAI).....	34
histology.....	42–3, 60, 97
HIV.....	26–9, 35,
47, 55, 61, 66, 75–6, 80, 82–3, 85–7, 89–90, 104	
• HBV-HIV coinfection.....	27, 44, 52, 63, 78–9
HIV Observational Database.....	78
Hong Kong immigrants.....	15
household contacts.....	
.....	35, 40, 46–7, 52, 75, 77, 83, 85, 102, 104–5

I	
immunosuppression.....	35, 43, 47, 49, 54, 75, 80
'inactive carrier'.....	41–2
incubation.....	31, 41
Indigenous Australians.....	
• high risk group.....	18–19, 40
• liver cancer.....	15–16
• prevalence.....	14–16, 35, 47
• vaccination.....	15, 47, 50
Infanrix HepB.....	48
Infanrix Hexa.....	48
Infanrix Penta.....	48
infant vaccination programs.....	9, 18, 46–9, 71, 76–7, 85, 104
infection control.....	82–9
Infection Control Guidelines for the Prevention of Transmission of Infectious Diseases in the Health Care Setting.....	82–4, 87
informed consent.....	36, 90, 93
injecting drug users.....	
• disease pattern.....	17
• HBV-HCV coinfection.....	17, 79
• HBV-HDV coinfection.....	79
• HBV transmission.....	40, 46, 102, 104
• prevalence.....	13–14, 17–18
• vaccination.....	47, 85, 104
intellectually disabled people.....	47
interferon based-therapy.....	10, 33, 55, 57, 59–63, 65–6, 72, 77–80, 97–8, 103
Ishak modified HAI.....	34

J	
jaundice.....	11, 41, 53, 66, 102

K	
kava.....	98–9
kurorinone.....	97–9

L	
lamivudine (LMV).....	
.....	10, 25, 27–9, 44, 55, 57, 59–62, 76–80, 97–8, 103
Larea tridentata (chaparral).....	96, 98
lifestyle issues.....	103
liver biopsy.....	9, 33–5, 43, 53, 55, 57–9, 70, 103
• liver cancer <i>see</i> hepatocellular carcinoma (HCC).....	
liver enzymes.....	53
liver function tests.....	42, 53–4, 62

liver transplantation..... 11, 58, 62, 65, 69–72, 85
 liver ultrasound..... 53–5, 69–70, 77, 103

M

magnetic resonance imaging (MRI)..... 70
 mandatory notification..... 14
 medical records..... 93–5
 Medical Services Advisory Committee..... 33
 men who have sex with men (MSM)
 • high-risk behaviour..... 19, 40
 • HIV-HBV coinfection..... 78
 • prevalence..... 14, 18, 47
 • vaccination..... 18, 47, 104
Mentha pulgium (pennyroyal)..... 96, 98
 METAVIR system..... 34–5
 Models of Care database..... 91, 93
 monitoring treatment..... 19, 33, 35, 54, 57–8, 61–2, 67–8, 77
 multi-drug resistance..... 28
 multidisciplinary teams..... 94
 mutations..... 24, 26–9, 33, 43, 50, 53, 55, 62, 76, 78, 80

N

National Herbalists Association of Australia (NHAA)..... 96, 99
 National Notifiable Diseases Surveillance System..... 8, 14
 needlestick injury..... 85–7, 94, 102
 New Zealand National Hepatitis B Programme..... 7, 72
 non-invasive assessment..... 34–5
 notifiable disease..... 90–1, 93
 NSW Needlestick Injury Hotline..... 87
 nucleoside and nucleotide analogues (NA)
 24–5, 27–9, 54–5, 58, 61–3, 65

O

occult HBV..... 29, 34, 43–4, 78–9
 occupational health..... 47, 82–9
Ocimum basilicum (sweet basil)..... 97
 Office of the Privacy Commissioner..... 91–3, 95
 overlapping open reading frames (ORF)..... 25
 oxymatrine..... 96–7, 99

P

paediatric management..... 77–8
Passiflora incarnata (passionflower)..... 98
 pegylated interferon..... 10, 55, 57, 59–65, 77–9, 103
 percutaneous ablation..... 11, 69, 71
 peripheral oedema..... 52
 Pharmaceutical Benefits Advisory Committee..... 55, 59
 Pharmaceutical Benefits Scheme..... 55, 58–62, 76, 78
Phyllanthus..... 98–9

Piper methysticum (kava)..... 98
 pol-env overlap..... 28
 • Pol ORF *see* reverse transcriptase/DNA polymerase (Pol ORF)
 polyarteritis nodosa..... 52
 polymerase chain reaction (PCR) assays..... 9, 32, 43, 53, 83
 polymerase mutations..... 27–9
 portal hypertension..... 11, 66–8
 portal systemic encephalopathy..... 66–8
 post-exposure prophylaxis (PEP)..... 87
 precautions against transmission..... 104
 'precore mutant' HBV..... 26, 33, 42–3, 53
 preferred terminology..... 41
 pregnancy..... 55, 63, 75–6
 premature infants..... 48
 prevalence..... 13–19, 35, 47
 prevention..... 46–50
 prisoners..... 17, 19, 47, 104
 privacy..... 90–5
 Privacy Act 1988 (Commonwealth)..... 90–1, 94
 prophylaxis
 • health care workers..... 87
 • during immunosuppressive therapy..... 80
 • pregnancy..... 76–7
 protective equipment..... 84
 prothrombin time..... 53–4
 Public Health Act 1991 (NSW)..... 93
 public health programs..... 18, 71–2
 pyrrolizidine alkaloids..... 98

R

reactivation..... 10–11, 32, 34, 41–3, 57, 75, 78–80
 rescue therapy..... 28
 REVEAL study..... 44
 reverse transcriptase..... 24–6, 28
 reverse transcriptase/DNA polymerase (Pol ORF)..... 25
 risk factors..... 17–19, 40, 51
 rituximab..... 10

S

safe sex..... 104
Salvia miltiorrhiza (scarlet root; Dan Shen)..... 97
 screening..... 11, 35, 46–7, 69, 71, 85
 • antenatal..... 76
 • effectiveness..... 7
 • HCC screening..... 55, 68–72, 77
Scutellaria baicalensis (baical skullcap)..... 97
Scutellaria laterifolia (skullcap)..... 98
 sex workers..... 40, 47, 104

sexual contacts	18, 35, 37, 46–7, 52, 85, 102, 104–5
sharps injury	85–7
shosaiko-to	97
side effects of treatment	63
silibinin	98
Silybum marianum (Saint Mary's thistle)	98
Sophora flavescens	97
splenomegaly	52, 66
surgical resection	69, 71

T

tattoos	40, 46–7, 50, 85, 102
telbivudine (L-dT)	10, 25, 27–9, 61
tenofovir disoproxil fumarate (TDF)	10, 27–8, 61, 63, 78
test results	31–7, 52–3, 58–9
testing	31–7, 52–4, 62, 86, 103
• <i>see also</i> clinical assessment	
Teucrium chamaedrys (wall germander)	96, 98
Teucrium polium	96, 98
Therapeutic Goods Administration (TGA)	59
TJ-9	97
transarterial chemoembolisation (TACE)	11, 71
transcatheter arterial embolisation (TAE)	71
transmission	40, 46, 50, 52, 75–6, 83, 87–8, 102
• vertical	40, 75–6, 102
transmission offences	95
transmission risk	52
transplant recipients	26, 47, 50, 85
travellers	47, 85, 104
treatment	57–63, 103
• <i>see also</i> antiviral agents; drug resistance; side effects	
Twinrix	48–9

V

vaccination programs	46–50
• accelerated schedules	48–9
• adolescents and adults	9, 47–8
• booster doses	49
• catch-up schedules	49
• effectiveness	12
• health care workers	49, 82, 85, 87, 89, 104
• Indigenous Australians	15–16, 47, 50
• infants	9, 46–9, 77
• National Immunisation Program: 2007	48
• non-response	49–50
• pregnancy	76
• recommended recipients	104
• regime	85–6

vaccine failure	26, 50
vaccines	48
vertical transmission	40, 75–6, 102
Vietnamese immigrants	8, 13–15, 18, 70
viral load	26, 29, 43, 60, 76, 79–80, 83
virology	24–9

W

wogonin (<i>Scutellaria baicalensis</i>)	96
World Health Organization (WHO)	8–9, 46